1. Broad-Spectrum ICU Empiric Therapy
A. Severe Sepsis / Septic Shock (unknown source)
Option 1 (most common):
✔ Piperacillin–Tazobactam (Zosyn)
4.5 g IV q6h
Covers gram +/–, anaerobes, Pseudomonas
✔ Vancomycin
(15–20 mg/kg; trough goal 15–20)
Covers MRSA
Option 2 (if renal failure or concern for ESBL):
✔ Meropenem 1–2 g IV q8h (extended infusion)
+
✔ Vancomycin
Option 3 (if hemodynamic instability with high MDR risk):
✔ Meropenem
+
✔ Vancomycin
+
✔ Amikacin or Tobramycin (single loading dose)
2. Pneumonia (ICU CAP, HAP, VAP)
A. Community-Acquired Pneumonia (ICU)
✔ Ceftriaxone 2 g IV daily
+
✔ Azithromycin 500 mg IV daily
or
✔ Levofloxacin 750 mg IV daily
If MRSA concern:
-
Vancomycin or Linezolid
B. Hospital-Acquired (HAP) / Ventilator-Associated Pneumonia (VAP)
✔ Zosyn 4.5 g q6h or Cefepime 2 g q8h
Covers Pseudomonas
✔ Vancomycin (MRSA)
If high MDR risk:
✔ Amikacin 15–20 mg/kg once
or
✔ Levofloxacin
3. Meningitis / Encephalitis (ICU)
✔ Ceftriaxone 2 g q12h
✔ Vancomycin
+
✔ Acyclovir 10 mg/kg q8h
+
Age > 50 or immunocompromised:
✔ Ampicillin (Listeria coverage)
4. Abdominal Infection / Intra-abdominal Sepsis
✔ Zosyn
or
✔ Meropenem (if severe or ESBL risk)
+
✔ Vancomycin (if source unclear or healthcare-associated)
5. Urosepsis / Pyelonephritis
✔ Cefepime
or
✔ Zosyn
If ESBL risk:
✔ Ertapenem or Meropenem
Add Vanco if concern for catheter-associated or MRSA.
6. Skin & Soft-Tissue Infection / Cellulitis (ICU)
✔ Vancomycin
+
If necrotizing / toxic-appearing:
✔ Piperacillin–Tazobactam
+
✔ Clindamycin (to block toxin production)
7. Endocarditis (ICU)
-
Vancomycin
-
Cefepime (or gentamicin depending on organism)
Specialized regimens based on organism & French endocarditis guidelines.
8. C. difficile colitis (Severe/Fulminant)
✔ Oral Vancomycin 125–500 mg q6h
+
✔ IV Metronidazole for fulminant disease
Avoid IV-only therapy (ineffective in gut lumen).
9. Antifungals (ICU)
Used when high suspicion for invasive fungal infection:
✔ Micafungin 100 mg IV daily
✔ Fluconazole 400–800 mg IV daily (if Candida albicans)
If immunocompromised / mold coverage:
✔ Voriconazole or Posaconazole
10. Antivirals (ICU)
Respiratory viral infections:
✔ Oseltamivir 75 mg BID
✔ Acyclovir for HSV/VZV encephalitis
✔ Ganciclovir for CMV reactivation
Renal Adjustment (CRRT, AKI)
-
Vancomycin: trough goal 15–20; careful in renal failure
-
Zosyn: extend to q8h in CRRT
-
Meropenem: extended infusion (3-hour infusion) improves outcomes
-
Aminoglycosides: single high dose only (concentration-dependent)
ICU Antibiotic Principles
-
Time matters: Start antibiotics within 1 hour in shock
-
De-escalate after cultures return
-
Use extended infusions for β-lactams in septic shock
-
Source control is often more important than antibiotics alone
-
Check MICs for Pseudomonas and MRSA
-
Beware nephrotoxicity: Vanco + Zosyn together increases AKI risk
Comment 0
| No. | Subject | Author | Date | Views |
|---|---|---|---|---|
| 25 | Cardiogenic shock in ICU | Drhyo | 2025.11.16 | 17 |
| 24 | PE in ICU | Drhyo | 2025.11.16 | 16 |
| 23 | ICU Hemodynamic Values | Drhyo | 2025.11.16 | 14 |
| 22 | IVC | Drhyo | 2025.11.16 | 15 |
| 21 | AKI in ICU | Drhyo | 2025.11.16 | 18 |
| 20 | ICU steroid use | Drhyo | 2025.11.16 | 13 |
| » | ICU EMPIRIC ANTIBIOTICS | Drhyo | 2025.11.16 | 17 |
| 18 | ARDS Vent management | Drhyo | 2025.11.16 | 19 |
| 17 | NIV | Drhyo | 2025.11.16 | 12 |
| 16 | High Anion Gap Metabolic Acidosis MUDPILES | Drhyo | 2025.11.16 | 13 |
| 15 | Quick ICU ABG cause and treatment | Drhyo | 2025.11.16 | 13 |
| 14 | ABG Interpretation | Drhyo | 2025.11.16 | 14 |
| 13 | ABG example | Drhyo | 2025.11.16 | 13 |
| 12 | Paracentesis | Drhyo | 2025.11.16 | 16 |
| 11 | Thoracentesis | Drhyo | 2025.11.16 | 14 |
| 10 | Intubation | Drhyo | 2025.11.16 | 11 |
| 9 | ICU sedative, analgesics, paralytics table | Drhyo | 2025.11.16 | 17 |
| 8 | ICU Sedation Guide | Drhyo | 2025.11.16 | 17 |
| 7 | ICU pressors table | Drhyo | 2025.11.16 | 9 |
| 6 | ICU Pressors: Types, Doses, Receptors, Clinical Use | Drhyo | 2025.11.16 | 13 |